Drug intelligence / Profile preview

SPR300

Development stage: Phase 1
Lead developer: Futura Medical
Modality: Small Molecules
Administration: Topical

Overview

**SPR300** is an investigational fixed-dose topical analgesic gel developed by Futura Medical. Public sources identify it as a methyl salicylate + menthol formulation, reported to use Futura's DermaSys skin-delivery technology. It was evaluated in a randomized, double-blind Phase 1 crossover study in healthy volunteers using a UV-induced inflammatory-pain model; no marketed brand name or later-stage clinical development has been confirmed. ([hra.nhs.uk](https://www.hra.nhs.uk/planning-and-improving-research/application-summaries/research-summaries/study-to-compare-efficacy-and-safety-of-topical-dcf100-tib200spr300/))

Other names: methyl salicylate + menthol

Targets

PTGS2 (Prostaglandin-Endoperoxide Synthase 2)TRPA1 (Transient receptor potential cation channel subfamily A member 1)PGHS-1 (Prostaglandin G/H Synthase 1)

Beyond the preview

Go deeper on SPR300.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SPR300.

Explore the full profile